Bristol-Myers Squibb opens the week with strategy focus, shares trade on NYSE

Bristol-Myers Squibb starts the week with investors watching its long-term growth strategy, from patent expiries to late-stage pipeline assets, while the shares continue to trade in the mid-50s USD range on the NYSE.

By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-22, 15:34.

Bristol-Myers Squibb (US1078421011) begins the new week with investors reassessing its long-term growth strategy in the U.S. large-cap pharmaceutical space. The company’s shares trade on the NYSE in the mid-50s USD range, according to recent quote data from MarketBeat and TradingKey. MarketBeat price overview

What current data show

Bristol-Myers Squibb is part of the S&P 500 and competes with peers such as Pfizer and Merck for oncology and immunology market share, keeping it in focus for U.S. and international investors. Recent quote snapshots place the shares around 54 USD, with MarketBeat reporting a last regular-session close at 54.10 USD on 18 June 2026. MarketBeat trading data

Additional intraday data compiled by FinancialData.net indicate that Bristol-Myers Squibb traded at approximately 54.41 USD on 22 June 2026 at 09:26 Eastern Time, implying a modest positive move of 0.76 percent during that snapshot. FinancialData.net quote table

Analyst stance and consensus

Analyst compilations on TradingKey describe Bristol-Myers Squibb with an overall Hold-type stance, summarised as a "signal_hold" rating, and cite an average price target of roughly 62.06 USD per share for BMY. TradingKey analyst summary

This consensus target implies upside of several dollars compared to recent mid-50s trading levels, underlining that many analysts still see valuation support despite concerns around upcoming patent expiries on major legacy drugs and the execution risk in the group’s late-stage pipeline. TradingKey valuation view

How Bristol-Myers Squibb earns its money

Bristol-Myers Squibb generates its revenue largely from prescription medicines in oncology, cardiovascular disease and immunology. Key products include the anticoagulant Eliquis, the immuno-oncology antibody Opdivo and the multiple myeloma treatment Revlimid, alongside a portfolio of other specialty therapies.

Where the stock trades today

The Bristol-Myers Squibb shares (US1078421011) trade on the NYSE at about 54.41 USD as of 2026-06-22, 09:26 Eastern Time, based on FinancialData.net quote data.

Bristol-Myers Squibb at a glance

• Company: Bristol-Myers Squibb Company
• ISIN: US1078421011
• WKN: 850501
• Ticker: BMY
• Trading venue: NYSE
• Price (as of 2026-06-22, 09:26): 54.41 USD
• Market cap: 110.84 billion USD (as of 2026-06-22)
• Sector / industry: Pharmaceuticals / Biotechnology
• Index membership: S&P 500
• Next earnings date: not officially scheduled

Disclaimer: This article is for informational purposes only and does not constitute investment advice, investment recommendation or an invitation to buy or sell securities. Investors should conduct their own research or consult a qualified financial advisor before making investment decisions.